Study of Vacc-4x Combined with Celgene`s Revlimid® Approved to Begin
Oslo 13.08.2012 – Study of Vacc-4x Combined with Celgene`s Revlimid® (lenalidomide) in HIV Patients with Impaired Immune System Approved to Begin News Summary Placebo-controlled, double-blind clinical study combining Vacc-4x with Celgene`s Revlimid® (lenalidomide) approved to start at four clinics in Germany Study seeks to improve the immunological response in patients who have failed to recover …